Lower cerebrospinal fluid (CSF) levels of neuronal pentraxin receptor (NPTXR) are associated with Alzheimer's disease (AD), but few studies show longitudinal changes in CSF NPTXR. In the present study, CSF NPTXR was measured at 0, 12, and 24 months using an enzyme-linked immunosorbent assay. The study groups included 28 patients with mild cognitive impairment (MCI) (MCI-MCI), 27 MCI patients who progressed to AD (MCI-AD) during the study, and 28 AD patients (AD-AD). Baseline levels were assessed for 46 control individuals. AD patients had lower baseline CSF NPTXR than controls (p = 0.023). Linear mixed models estimated a 6.7% annualized decrease in CSF NPTXR in the AD-AD group, significantly different from MCI-MCI (p = 0.03) and MCI-AD groups (p = 0.048). CSF NPTXR did not correlate with CSF Aβ42 and weakly correlated with CSF Aβ40, T-tau, P-tau (all R2 < 0.22, p < 0.06). These trends suggest CSF NPTXR may be a candidate biomarker of AD progression but not sufficiently sensitive to resolve when patients convert from MCI to dementia.

中文翻译：

---

脑脊液神经元五联蛋白受体作为阿尔茨海默病长期进展的生物标志物：一项为期 24 个月的随访研究。

较低的脑脊液 (CSF) 神经元五联蛋白受体 (NPTXR) 水平与阿尔茨海默病 (AD) 相关，但很少有研究显示 CSF NPTXR 的纵向变化。在本研究中，使用酶联免疫吸附测定法在 0、12 和 24 个月时测量了 CSF NPTXR。研究组包括 28 名轻度认知障碍 (MCI) 患者 (MCI-MCI)、27 名在研究期间进展为 AD 的 MCI 患者 (MCI-AD) 和 28 名 AD 患者 (AD-AD)。评估了 46 名对照个体的基线水平。AD 患者的基线 CSF NPTXR 低于对照组（p = 0.023）。线性混合模型估计 AD-AD 组 CSF NPTXR 年化下降 6.7%，与 MCI-MCI (p = 0.03) 和 MCI-AD 组 (p = 0.048) 显着不同。CSF NPTXR 与 CSF Aβ42 不相关，与 CSF Aβ40、T-tau、P-tau（所有 R2 < 0.22，p < 0.06）。这些趋势表明 CSF NPTXR 可能是 AD 进展的候选生物标志物，但当患者从 MCI 转变为痴呆时，其敏感性不足以解决问题。